scholarly journals Toxic Shock Syndrome Toxin 1-Producing Methicillin-Resistant Staphylococcus aureus of Clonal Complex 5, the New York/Japan Epidemic Clone, Causing a High Early-Mortality Rate in Patients with Bloodstream Infections

2019 ◽  
Vol 63 (11) ◽  
Author(s):  
Dokyun Kim ◽  
Jun Sung Hong ◽  
Eun-Jeong Yoon ◽  
Hyukmin Lee ◽  
Young Ah Kim ◽  
...  
Keyword(s):  
Risk Factors ◽  
New York ◽  
Staphylococcus Aureus ◽  
Mortality Rate ◽  
Clonal Complex ◽  
Bloodstream Infections ◽  
Early Mortality ◽  
Epidemic Clone ◽  
Methicillin Resistant ◽  
Content Type

ABSTRACT This study was performed to evaluate the clinical impacts of putative risk factors in patients with Staphylococcus aureus bloodstream infections (BSIs) through a prospective, multicenter, observational study. All 567 patients with S. aureus BSIs that occurred during a 1-year period in six general hospitals were included in this study. Host- and pathogen-related variables were investigated to determine risk factors for the early mortality of patients with S. aureus BSIs. The all-cause mortality rate was 15.0% (85/567) during the 4-week follow-up period from the initial blood culture, and 76.5% (65/85) of the mortality cases occurred within the first 2 weeks. One-quarter (26.8%, 152/567) of the S. aureus blood isolates carried the tst-1 gene, and most (86.2%, 131/152) of them were identified to be clonal complex 5 agr type 2 methicillin-resistant S. aureus (MRSA) strains harboring staphylococcal cassette chromosome mec type II, belonging to the New York/Japan epidemic clone. A multivariable logistic regression showed that the tst-1 positivity of the causative S. aureus isolates was associated with an increased 2-week mortality rate both in patients with S. aureus BSIs (adjusted odds ratio [aOR], 1.62; 95% confidence interval [CI], 0.90 to 2.88) and in patients with MRSA BSIs (aOR, 2.61; 95% CI, 1.19 to 6.03). Two host-related factors, an increased Pitt bacteremia score and advanced age, as well as a pathogen-related factor, carriage of tst-1 by causative MRSA isolates, were risk factors for 2-week mortality in patients with BSIs. Careful management of patients with BSIs caused by the New York/Japan epidemic clone is needed to improve clinical outcomes.

scholarly journals Predictors ofagrDysfunction in Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates among Patients with MRSA Bloodstream Infections

2011 ◽  
Vol 55 (12) ◽  
pp. 5433-5437 ◽  
Author(s):  
Jill M. Butterfield ◽  
Brian T. Tsuji ◽  
Jack Brown ◽  
Elizabeth Dodds Ashley ◽  
Dwight Hardy ◽  
...  
Keyword(s):  
New York ◽  
Staphylococcus Aureus ◽  
Severity Of Illness ◽  
Bloodstream Infections ◽  
Bivariate Analysis ◽  
Beta Lactam ◽  
Accessory Gene ◽  
Cross Sectional ◽  
Methicillin Resistant ◽  
Content Type

ABSTRACTDespite emerging evidence that dysfunction in the accessory gene regulator (agr) locus is associated with deleterious outcomes among patients treated with vancomycin for methicillin-resistantStaphylococcus aureus(MRSA) infections, factors predictive ofagrdysfunction have not been evaluated. This study describes the epidemiology ofagrdysfunction, identifies predictors ofagrdysfunction in MRSA isolates among those with MRSA bloodstream infections, and describes the relationship betweenagrdysfunction and other microbiologic phenotypes. A cross-sectional study of patients with MRSA bloodstream infections at two institutions in upstate New York was performed. Clinical data on demographics, comorbidities, disease severity, hospitalization history, and antibiotic history were collected. Microbiologic phenotypes, includingagrdysfunction, MIC values by broth microdilution (BMD) and Etest, and vancomycin heteroresistance (hVISA) were tested. Multivariable analyses were performed to identify factors predictive ofagrdysfunction. Among 200 patients with an MRSA bloodstream infection, the proportion of strains withagrdysfunction was 31.5%. The distribution of MICs determined by both BMD and Etest were equivalent acrossagrgroups, and there was no association betweenagrdysfunction and the presence of hVISA. Severity of illness, comorbidities, and hospitalization history were comparable betweenagrgroups. In the multivariate analysis, prior antibiotic exposure was the only factor of variables studied found to be predictive ofagrdysfunction. This relationship was predominantly driven by prior beta-lactam and fluoroquinolone administration in the bivariate analysis. Identifying these institution-specific risk factors can be used to develop a process to assess the risk ofagrdysfunction and guide empirical antibiotic therapy decisions.

scholarly journals Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in anIn VitroPharmacokinetic/Pharmacodynamic Model

2015 ◽  
Vol 59 (8) ◽  
pp. 4497-4503 ◽  
Author(s):  
Katie E. Barber ◽  
Jordan R. Smith ◽  
Cortney E. Ireland ◽  
Blaise R. Boles ◽  
Warren E. Rose ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Medical Device ◽  
Bloodstream Infections ◽  
Methicillin Resistant ◽  
Content Type ◽  
Elimination Half ◽  
Antimicrobial Protection ◽  
Mrsa Strains ◽  
Post Hoc

ABSTRACTAnnually, medical device infections are associated with >250,000 catheter-associated bloodstream infections (CLABSI), with up to 25% mortality.Staphylococcus aureus, a primary pathogen in these infections, is capable of biofilm production, allowing organism persistence in harsh environments, offering antimicrobial protection. With increases inS. aureusisolates with reduced susceptibility to current agents, ceftaroline (CPT) offers a therapeutic alternative. Therefore, we evaluated whether CPT would have a role against biofilm-producing methicillin-resistantS. aureus(MRSA), including those with decreased susceptibilities to alternative agents. In this study, we investigated CPT activity alone or combined with daptomycin (DAP) or rifampin (RIF) against 3 clinical biofilm-producing MRSA strains in anin vitrobiofilm pharmacokinetic/pharmacodynamic (PK/PD) model. Simulated antimicrobial regimens were as follows: 600 mg of CPT every 8 h (q8h) (free maximum concentration of drug [fCmax], 17.04 mg/liter; elimination half-life [t1/2], 2.66 h), 12 mg/kg of body weight/day of DAP (fCmax, 14.7 mg/liter;t1/2, 8 h), and 450 mg of RIF q12h (fCmax, 3.5 mg/liter;t1/2, 3.4 h), CPT plus DAP, and CPT plus RIF. Samples were obtained and plated to determine colony counts. Differences in log10CFU/cm2were evaluated by analysis of variance with Tukey'spost hoctest. The strains were CPT and vancomycin susceptible and DAP nonsusceptible (DNS). CPT displayed activity throughout the experiment. DAP demonstrated initial activity with regrowth at 24 h in all strains. RIF was comparable to the drug-free control, and little benefit was observed when combined with CPT. CPT plus DAP displayed potent activity, with an average log10CFU/cm2reduction of 3.33 ± 1.01 from baseline. CPT demonstrated activity against biofilm-producing DNS MRSA. CPT plus DAP displayed therapeutic enhancement over monotherapy, providing a potential option for difficult-to-treat medical device infections.

scholarly journals Blurred molecular epidemiological lines between the two dominant methicillin-resistant Staphylococcus aureus clones

2018 ◽  
Author(s):  
Amy C. Dupper ◽  
Mitchell J. Sullivan ◽  
Kieran I. Chacko ◽  
Aaron Mishkin ◽  
Brianne Ciferri ◽  
...  
Keyword(s):  
New York ◽  
Staphylococcus Aureus ◽  
Medical Center ◽  
Data Extraction ◽  
Age Groups ◽  
Bloodstream Infections ◽  
Methicillin Resistant ◽  
Peripheral Intravenous Catheter ◽  
Life Threatening ◽  
Healthcare Associated

AbstractBackgroundMethicillin-resistant Staphylococcus aureus (MRSA) causes life-threatening infections in both community and hospital settings and is a leading cause of healthcare-associated infections (HAIs). We sought to describe the molecular epidemiological landscape of patients with MRSA bloodstream infections (BSIs) at an urban medical center by evaluating the clinical characteristics associated with the two dominant endemic clones.MethodsComprehensive clinical data extraction from the electronic health records of 227 hospitalized patients ≥18 years old with MRSA BSI over a 33-month period in New York City were collected. The descriptive epidemiology and mortality associated with the two dominant clones was compared using logistic regression.ResultsMolecular analysis revealed that 91% of all single-patient MRSA BSIs were due to two equally represented genotypes, clonal complex (CC) 5 (N=117) and CC8 (N=110). MRSA BSIs were associated with a 90-day mortality of 27%. CC8 caused disease more frequently in younger age groups (56 ± 17 vs 67 ± 17 years old; p<0.001) and in non-White race (OR=3.45 95% CI [1.51-7.87]; p=0.003), with few other major distinguishing features. Morbidity and mortality also did not differ significantly between the two clones. CC8 caused BSIs more frequently in the setting of peripheral intravenous catheters (OR=5.96; 95% CI [1.51-23.50]; p=0.01).ConclusionThe clinical features distinguishing dominant MRSA clones continue to converge. The association of CC8 with peripheral intravenous catheter infections underscores the importance of classical community clones causing hospital-onset infections. Ongoing monitoring and analysis of the dynamic epidemiology of this endemic pathogen is crucial to inform management to prevent disease.

scholarly journals Scope and Predictive Genetic/Phenotypic Signatures of Bicarbonate (NaHCO3) Responsiveness and β-Lactam Sensitization in Methicillin-Resistant Staphylococcus aureus

2020 ◽  
Vol 64 (5) ◽  
Author(s):  
Selvi C. Ersoy ◽  
Mariam Otmishi ◽  
Vanessa T. Milan ◽  
Liang Li ◽  
Youngju Pak ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Clonal Complex ◽  
Population Analysis ◽  
Methicillin Resistant ◽  
Content Type ◽  
Mueller Hinton ◽  
Testing Medium ◽  
Mrsa Strains ◽  
Mueller Hinton Broth

ABSTRACT Addition of sodium bicarbonate (NaHCO3) to standard antimicrobial susceptibility testing medium reveals certain methicillin-resistant Staphylococcus aureus (MRSA) strains to be highly susceptible to β-lactams. We investigated the prevalence of this phenotype (NaHCO3 responsiveness) to two β-lactams among 58 clinical MRSA bloodstream isolates. Of note, ∼75% and ∼36% of isolates displayed the NaHCO3 responsiveness phenotype to cefazolin (CFZ) and oxacillin (OXA), respectively. Neither intrinsic β-lactam MICs in standard Mueller-Hinton broth (MHB) nor population analysis profiles were predictive of this phenotype. Several genotypic markers (clonal complex 8 [CC8]; agr I and spa t008) were associated with NaHCO3 responsiveness for OXA.

scholarly journals Novel Types of Staphylococcal Cassette ChromosomemecElements Identified in Clonal Complex 398 Methicillin-Resistant Staphylococcus aureus Strains

2011 ◽  
Vol 55 (6) ◽  
pp. 3046-3050 ◽  
Author(s):  
Shanshuang Li ◽  
Robert Leo Skov ◽  
Xiao Han ◽  
Anders Rhod Larsen ◽  
Jesper Larsen ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Clonal Complex ◽  
Subtype C ◽  
Methicillin Resistant ◽  
Content Type ◽  
Original Host ◽  
Mrsa Strains ◽  
Type V ◽  
Staphylococcal Cassette Chromosome

ABSTRACTThe structures of staphylococcal cassette chromosomemec(SCCmec) elements carried by 31 clonal complex 398 (CC398) methicillin-resistantStaphylococcus aureus(MRSA) strains isolated from the participants at a conference were analyzed. The SCCmecs were classified into novel types, namely, IX, X, V(5C2&5) subtype c, and IVa. Type V(5C2&5) subtype c, IX, and X SCCmecs carried genes conferring resistance to metals. The structures of SCCmecs from CC398 strains were distinct from those normally found in humans, adding to the evidence that humans are not the original host for CC398.

Incidence and risk factors for community-associated methicillin-resistant Staphylococcus aureus in New York City, 2006–2012

2015 ◽  
Vol 144 (5) ◽  
pp. 1014-1017 ◽  
Author(s):  
P. BAKER ◽  
B. COHEN ◽  
J. LIU ◽  
E. LARSON
Keyword(s):  
Risk Factors ◽  
New York ◽  
Staphylococcus Aureus ◽  
New York City ◽  
Logistic Regression ◽  
York City ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Methicillin Resistant ◽  
Factors Associated ◽  
History Of

SUMMARYThis study aims to describe changes in incidence and risk factors for community-associated methicillin resistant Staphylococcus aureus (CA-MRSA) infections upon admission to two New York City hospitals from 2006 to 2012. We examined the first hospitalization for adult patients using electronic health record and administrative data and determined the annual incidence/1000 admissions of total S. aureus, total MRSA, and CA-MRSA (within 48 h of admission) in clinical specimens over the study period. Logistic regression was used to identify factors associated with CA-MRSA in 2006 and 2012. In 137 350 admissions, the incidence of S. aureus, MRSA, and CA-MRSA/1000 admissions were 15·6, 7·0, and 3·5, respectively. The total S. aureus and MRSA isolations decreased significantly over the study period (27% and 25%, respectively) while CA-MRSA incidence was unchanged. CA-MRSA increased as a proportion of all MRSA between 2006 (46%) and 2012 (62%), and was most frequently isolated from respiratory (1·5/1000) and blood (0·7/1000) cultures. Logistic regression analysis of factors associated with isolation of CA-MRSA showed that age ⩾65 years [odds ratio (OR) 2·3, 95% confidence interval (CI) 1·2–4·5], male gender (OR 1·8, 95% CI 1·2–2·8) and history of renal failure (OR 2·6, 95% CI 1·6–4·2) were significant predictors of infection in 2006. No predictors were identified in 2012.

scholarly journals Methicillin-Resistant Staphylococcus aureus Control in the 21st Century: Laboratory Involvement Affecting Disease Impact and Economic Benefit from Large Population Studies

2016 ◽  
Vol 54 (11) ◽  
pp. 2647-2654 ◽  
Author(s):  
Lance R. Peterson ◽  
Donna M. Schora
Keyword(s):  
Health Care ◽  
Staphylococcus Aureus ◽  
Disease Control ◽  
Clinical Laboratory ◽  
Large Population ◽  
Bloodstream Infections ◽  
Control Plan ◽  
Methicillin Resistant ◽  
Content Type ◽  
Program Cost

Methicillin-resistant Staphylococcus aureus (MRSA) infection is a global health care problem. Large studies (e.g., >25,000 patients) show that active surveillance testing (AST) followed by contact precautions for positive patients is an effective approach for MRSA disease control. With this approach, the clinical laboratory will be asked to select what AST method(s) to use and to provide data monitoring outcomes of the infection prevention interventions. This minireview summarizes evidence for MRSA disease control, reviews the involvement of the laboratory, and provides examples of how to undertake a program cost analysis. Health care organizations with total MRSA clinical infections of >0.3/1,000 patient days or bloodstream infections of >0.03/1,000 patient days should implement a MRSA control plan.

scholarly journals Epidemiology of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections from 2013-2017 at Chiang Mai University: What Changes Occurred from 2007-2011?

2020 ◽  
Author(s):  
Kawisara Krasaewes ◽  
Saowaluck Yasri ◽  
Phadungkiat Khamnoi ◽  
Romanee Chaiwarith
Keyword(s):  
Staphylococcus Aureus ◽  
Mortality Rate ◽  
Methicillin Resistance ◽  
Bloodstream Infections ◽  
Arterial Graft ◽  
Chiang Mai ◽  
Methicillin Resistant ◽  
Vancomycin Mics ◽  
Significant Difference ◽  
Tract Infections

Abstract Background: Methicillin-resistant Staphylococcus aureus (MRSA) is an established pathogen that causes hospital- acquired infections worldwide. Bloodstream infection is associated with significant morbidity and mortality. We conducted a study aimed at describing the epidemiology of MRSA bloodstream infections, to determine the minimal inhibitory concentration (MIC) of the antibiotic vancomycin among MRSA isolates, and to determine the rate and risk factors of mortality.Methods: A retrospective study was conducted among patients aged ≥ 18 years whose blood culture grew MRSA at Chiang Mai University from January 2013 to December 2017Results: The annual prevalence of MRSA in S.aureus bloodstream infections from 2013 to 2017 were 32.8, 23.1, 26.8, 19.2 and 15.4%, respectively. This prevalence showed a non-significant decrease (p = 0.086). Eighty-four patients with 84 episodes of MRSA bloodstream infections were enrolled. Fifty-three patients (63.1%) were male, and the median age was 68.5 years (IQR 56, 79). Fifty-eight patients (69%) had bloodstream infections with other sites of infection: pneumonia (28 episodes, 43.1%), skin and soft tissue infections (16 episodes, 24.6%), osteomyelitis (7 episodes, 10.8%), infective endocarditis (4 episodes, 6.2%), septic arthritis (4 episodes, 6.2%), arterial graft infections (4 episodes, 6.2%), and urinary tract infections (2 episodes, 3.1%). Percentage of patients with vancomycin MICs ≥ 1.5 mg/L were 68.2%, 62.5%, 47.4%, 26.7%, and 75% from 2013 to 2017, respectively. (p = 0.325). The mortality rate was 64.3%. There was no significant difference in mortality rate between those infected with MRSA with a MIC of vancomycin < 1.5 and ≥ 1.5 mg/L (p = 0.172). Factors associated with mortality included age ≥ 40 years old (OR 11.35; 95% CI: 1.35–95.78, p = 0.026), presence of alteration of consciousness (OR 11.19; 95% CI: 2.83–44.18, p = 0.001) and concurrent pneumonia (OR 4.44; 95% CI: 1.09–18.14, p = 0.038).Conclusions: Methicillin-resistance among Staphylococcus aureus bloodstream infections showed a non-significant decrease of 50%, from 32.88% and 15.4%, between 2013 and 2017. Concurrent infection with pneumonia increased mortality. Although the vancomycin MIC was unchanged from 2013 to 2017, the mean MICs were > 1.0 mg/L. Careful monitoring of vancomycin MIC creep is crucial for the selection of the appropriate antibiotic dosage to prevent treatment failure.

scholarly journals High Prevalence of Mupirocin Resistance in Staphylococcus aureus Isolates from a Pediatric Population

2015 ◽  
Vol 59 (6) ◽  
pp. 3350-3356 ◽  
Author(s):  
Nina K. Antonov ◽  
Maria C. Garzon ◽  
Kimberly D. Morel ◽  
Susan Whittier ◽  
Paul J. Planet ◽  
...  
Keyword(s):  
Risk Factors ◽  
New York ◽  
Staphylococcus Aureus ◽  
New York City ◽  
York City ◽  
Methicillin Resistance ◽  
Strong Association ◽  
Resistant Isolate ◽  
Content Type ◽  
Mupirocin Resistance

ABSTRACTTopical mupirocin is used widely to treat skin and soft tissue infections and to eradicate nasal carriage of methicillin-resistantStaphylococcus aureus(MRSA). Few studies to date have characterized the rates ofS. aureusmupirocin resistance in pediatric populations. We retrospectively studied 358 uniqueS. aureusisolates obtained from 249 children seen in a predominantly outpatient setting by the Division of Pediatric Dermatology at a major academic center in New York City between 1 May 2012 and 17 September 2013. Mupirocin resistance rates and the associated risk factors were determined using a logistic regression analysis. In our patient population, 19.3% of patients had mupirocin-resistantS. aureusisolates at the time of their first culture, and 22.1% of patients withS. aureusinfection had a mupirocin-resistant isolate at some time during the study period. Overall, 31.3% of allS. aureusisolates collected during the study period were resistant to mupirocin. Prior mupirocin use was strongly correlated (odds ratio [OR] = 26.5;P= <0.001) with mupirocin resistance. Additional risk factors for mupirocin resistance included methicillin resistance, atopic dermatitis (AD), epidermolysis bullosa (EB), immunosuppression, and residence in northern Manhattan and the Bronx. Resistance to mupirocin is widespread in children with dermatologic complaints in the New York City area, and given the strong association with mupirocin exposure, it is likely that mupirocin use contributes to the increased resistance. Routine mupirocin testing may be important for MRSA decolonization strategies or the treatment of minor skin infections in children.

scholarly journals Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

2016 ◽  
Vol 61 (2) ◽  
Author(s):  
Evan J. Zasowski ◽  
Trang D. Trinh ◽  
Kimberly C. Claeys ◽  
Anthony M. Casapao ◽  
Noor Sabagha ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Combination Therapy ◽  
Observational Study ◽  
Clinical Success ◽  
Bloodstream Infections ◽  
Interquartile Range ◽  
Ceftaroline Fosamil ◽  
Methicillin Resistant ◽  
Content Type ◽  
Multicenter Observational Study

ABSTRACT Novel therapies for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI) are needed in the setting of reduced antibiotic susceptibilities and therapeutic failure. Ceftaroline is a cephalosporin antibiotic with MRSA activity. Although not FDA approved for MRSA BSI, ceftaroline has generated much interest as a potential treatment option. However, detailed descriptions of its use in this setting remain limited. To address this, we conducted a retrospective, multicenter, observational study of adult patients with MRSA BSI treated with at least 72 h of ceftaroline from 2011 to 2015. Safety outcomes were examined in the overall cohort, while efficacy outcomes were examined among patients who had not cleared their BSI prior to ceftaroline initiation. Data were also stratified by ceftaroline monotherapy or combination therapy. Predictors of clinical failure on ceftaroline treatment were also sought. Overall, 211 patients were included in the safety population; Clostridium difficile infection, rash, and neutropenia occurred in 6 patients (2.8%), 7 patients (3.3%), and 3 patients (1.4%), respectively. Clinical success was observed in 86 (68.3%) of the 126 patients included in the efficacy population. The monotherapy and combination therapy subgroups had similar proportions of patients experiencing success (69.7 and 64.9%, respectively). The median BSI durations post-ceftaroline treatment were 2 days (interquartile range, 1 to 4 days) for monotherapy and 3 days (interquartile range, 1.5 to 5 days) for combination therapy. Higher acute physiology and chronic health evaluation II scores and comorbid malignancy independently predicted treatment failure. Ceftaroline appears effective for MRSA BSI as both monotherapy and combination therapy. However, comparative studies are needed to further delineate the role of ceftaroline in MRSA BSI treatment.

Sign in / Sign up

Export Citation Format

Share Document